HIV neuropathy

Gulshan Doulatram, Tilak Raj, William Yancey

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

A 44-year-old male presents with burning in both legs for the past 8 months which has become severe in the last 2 months. He has been diagnosed with HIV for the past 3 years. His current CD4+ cell count is 250 cells/ul and viral load 50 copies/ml. He was started on highly active antiretroviral therapy (HAART) about 3 months ago. He smokes marijuana and insists that it helps with his pain. 1. How prevalent is this disease presentation? Could you explain some of the epidemiologic features of this disease? Are there any cost concerns? In its 2012 HIV Surveillance Supplemental Report, the Centers for Disease Control estimates that over 1.1 million persons in the USA are infected with HIV, and predicts an additional 50 000 new infections each year.[1,2] The global prevalence of HIV is 33 million. These individuals are at risk for multiple neurologic complications due to their disease. The most common of these complications is distal symmetric polyneuropathy (DSP).[3,4] Its high prevalence ranks it as one of the more frequently encountered etiologies of neuropathic pain in the general population. As such, DSP is a substantial contributor to the healthcare cost of neuropathic pain as a whole. Berger et al examined this and demonstrated an average yearly healthcare cost of $17 355 for a patient with a painful neuropathic disorder versus $5715 for a matched control patient.[5]

Original languageEnglish (US)
Title of host publicationCase Studies in Pain Management
PublisherCambridge University Press
Pages72-80
Number of pages9
ISBN (Print)9781107281950, 9781107682894
DOIs
StatePublished - Jan 1 2014

Fingerprint

HIV
Polyneuropathies
Neuralgia
Health Care Costs
Highly Active Antiretroviral Therapy
Cannabis
Centers for Disease Control and Prevention (U.S.)
CD4 Lymphocyte Count
Viral Load
Smoke
Nervous System
Leg
Costs and Cost Analysis
Pain
Infection
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Doulatram, G., Raj, T., & Yancey, W. (2014). HIV neuropathy. In Case Studies in Pain Management (pp. 72-80). Cambridge University Press. https://doi.org/10.1017/CBO9781107281950.011

HIV neuropathy. / Doulatram, Gulshan; Raj, Tilak; Yancey, William.

Case Studies in Pain Management. Cambridge University Press, 2014. p. 72-80.

Research output: Chapter in Book/Report/Conference proceedingChapter

Doulatram, G, Raj, T & Yancey, W 2014, HIV neuropathy. in Case Studies in Pain Management. Cambridge University Press, pp. 72-80. https://doi.org/10.1017/CBO9781107281950.011
Doulatram G, Raj T, Yancey W. HIV neuropathy. In Case Studies in Pain Management. Cambridge University Press. 2014. p. 72-80 https://doi.org/10.1017/CBO9781107281950.011
Doulatram, Gulshan ; Raj, Tilak ; Yancey, William. / HIV neuropathy. Case Studies in Pain Management. Cambridge University Press, 2014. pp. 72-80
@inbook{74996ae0a77d4dd1bc5cc0c2d4ebfc65,
title = "HIV neuropathy",
abstract = "A 44-year-old male presents with burning in both legs for the past 8 months which has become severe in the last 2 months. He has been diagnosed with HIV for the past 3 years. His current CD4+ cell count is 250 cells/ul and viral load 50 copies/ml. He was started on highly active antiretroviral therapy (HAART) about 3 months ago. He smokes marijuana and insists that it helps with his pain. 1. How prevalent is this disease presentation? Could you explain some of the epidemiologic features of this disease? Are there any cost concerns? In its 2012 HIV Surveillance Supplemental Report, the Centers for Disease Control estimates that over 1.1 million persons in the USA are infected with HIV, and predicts an additional 50 000 new infections each year.[1,2] The global prevalence of HIV is 33 million. These individuals are at risk for multiple neurologic complications due to their disease. The most common of these complications is distal symmetric polyneuropathy (DSP).[3,4] Its high prevalence ranks it as one of the more frequently encountered etiologies of neuropathic pain in the general population. As such, DSP is a substantial contributor to the healthcare cost of neuropathic pain as a whole. Berger et al examined this and demonstrated an average yearly healthcare cost of $17 355 for a patient with a painful neuropathic disorder versus $5715 for a matched control patient.[5]",
author = "Gulshan Doulatram and Tilak Raj and William Yancey",
year = "2014",
month = "1",
day = "1",
doi = "10.1017/CBO9781107281950.011",
language = "English (US)",
isbn = "9781107281950",
pages = "72--80",
booktitle = "Case Studies in Pain Management",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - HIV neuropathy

AU - Doulatram, Gulshan

AU - Raj, Tilak

AU - Yancey, William

PY - 2014/1/1

Y1 - 2014/1/1

N2 - A 44-year-old male presents with burning in both legs for the past 8 months which has become severe in the last 2 months. He has been diagnosed with HIV for the past 3 years. His current CD4+ cell count is 250 cells/ul and viral load 50 copies/ml. He was started on highly active antiretroviral therapy (HAART) about 3 months ago. He smokes marijuana and insists that it helps with his pain. 1. How prevalent is this disease presentation? Could you explain some of the epidemiologic features of this disease? Are there any cost concerns? In its 2012 HIV Surveillance Supplemental Report, the Centers for Disease Control estimates that over 1.1 million persons in the USA are infected with HIV, and predicts an additional 50 000 new infections each year.[1,2] The global prevalence of HIV is 33 million. These individuals are at risk for multiple neurologic complications due to their disease. The most common of these complications is distal symmetric polyneuropathy (DSP).[3,4] Its high prevalence ranks it as one of the more frequently encountered etiologies of neuropathic pain in the general population. As such, DSP is a substantial contributor to the healthcare cost of neuropathic pain as a whole. Berger et al examined this and demonstrated an average yearly healthcare cost of $17 355 for a patient with a painful neuropathic disorder versus $5715 for a matched control patient.[5]

AB - A 44-year-old male presents with burning in both legs for the past 8 months which has become severe in the last 2 months. He has been diagnosed with HIV for the past 3 years. His current CD4+ cell count is 250 cells/ul and viral load 50 copies/ml. He was started on highly active antiretroviral therapy (HAART) about 3 months ago. He smokes marijuana and insists that it helps with his pain. 1. How prevalent is this disease presentation? Could you explain some of the epidemiologic features of this disease? Are there any cost concerns? In its 2012 HIV Surveillance Supplemental Report, the Centers for Disease Control estimates that over 1.1 million persons in the USA are infected with HIV, and predicts an additional 50 000 new infections each year.[1,2] The global prevalence of HIV is 33 million. These individuals are at risk for multiple neurologic complications due to their disease. The most common of these complications is distal symmetric polyneuropathy (DSP).[3,4] Its high prevalence ranks it as one of the more frequently encountered etiologies of neuropathic pain in the general population. As such, DSP is a substantial contributor to the healthcare cost of neuropathic pain as a whole. Berger et al examined this and demonstrated an average yearly healthcare cost of $17 355 for a patient with a painful neuropathic disorder versus $5715 for a matched control patient.[5]

UR - http://www.scopus.com/inward/record.url?scp=84952845655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952845655&partnerID=8YFLogxK

U2 - 10.1017/CBO9781107281950.011

DO - 10.1017/CBO9781107281950.011

M3 - Chapter

SN - 9781107281950

SN - 9781107682894

SP - 72

EP - 80

BT - Case Studies in Pain Management

PB - Cambridge University Press

ER -